aHR | 95% CI | P | |
---|---|---|---|
Race | |||
Non-Hispanic White | Reference | ||
Hispanic White | 0.85 | 0.77–0.94 | 0.001 |
Black | 1.1 | 1.02–1.19 | 0.01 |
Asian/Pacific Islander | 0.66 | 0.56–0.77 | < 0.001 |
Age | |||
< 50 years | Reference | ||
50 years or older | 1.9 | 1.73–2.08 | < 0.001 |
Facility | |||
Nonacademic | Reference | ||
Academic | 0.79 | 0.75–0.83 | < 0.001 |
Insurance | |||
None | Reference | ||
Private | 0.62 | 0.51–0.76 | < 0.001 |
Government | 1.44 | 1.18–1.77 | < 0.001 |
Income | |||
Above median | Reference | ||
Below median | 1.17 | 1.11–1.25 | < 0.001 |
Education | |||
Above median | Reference | ||
Below median | 1.06 | 1.00–1.13 | 0.04 |
CDS | |||
0 | Reference | ||
1 | 1.59 | 1.50–1.68 | < 0.001 |
2 + | 2.72 | 2.51–2.95 | < 0.001 |
Year | |||
For every 1 year increase | 1.02 | 1.01–1.03 | 0.002 |
Histology | |||
Ductal or lobular carcinoma | Reference | ||
Other | 0.98 | 0.92–1.05 | 0.58 |
PR | |||
Positive | Reference | ||
Negative | 1.09 | 1.02–1.16 | 0.02 |
T staging | |||
1 | Reference | ||
2 | 1.49 | 1.42–1.57 | < 0.001 |
3 | 2.26 | 1.95–2.63 | < 0.001 |
N staging | |||
0 | Reference | ||
1a | 1.61 | 1.52–1.71 | < 0.001 |
RS | |||
0–15 | Reference | ||
16–25 | 1.16 | 1.10–1.22 | < 0.001 |
≥ 26 | 2.05 | 1.91–2.21 | < 0.001 |
Grade | |||
1 | Reference | ||
2 | 1.14 | 1.08–1.21 | < 0.001 |
3 | 1.5 | 1.39–1.61 | < 0.001 |
Other | 1.02 | 0.49–2.15 | 0.95 |
LVSI | |||
No | Reference | ||
Yes | 1.15 | 1.08–1.23 | < 0.001 |
Chemotherapy | |||
No | Reference | ||
Yes | 0.7 | 0.65–0.74 | < 0.001 |
Radiation | |||
No | Reference | ||
Yes | 0.6 | 0.55–0.64 | < 0.001 |
Surgery | |||
Lumpectomy | Reference | ||
Mastectomy | 0.73 | 0.67–0.79 | < 0.001 |
Other | 1.47 | 0.55–3.94 | 0.44 |
Margin | |||
Negative | Reference | ||
Positive | 1.18 | 1.04–1.33 | 0.008 |